Leerink Partnrs Has Negative Outlook for Geron Q4 Earnings

Geron Corporation (NASDAQ:GERN - Free Report) - Equities researchers at Leerink Partnrs decreased their Q4 2025 earnings per share estimates for Geron in a report released on Monday, July 21st. Leerink Partnrs analyst F. Khurshid now anticipates that the biopharmaceutical company will earn ($0.06) per share for the quarter, down from their prior forecast of ($0.05). The consensus estimate for Geron's current full-year earnings is ($0.25) per share. Leerink Partnrs also issued estimates for Geron's FY2026 earnings at ($0.06) EPS.

Other equities research analysts have also recently issued reports about the company. Scotiabank cut Geron from a "sector outperform" rating to a "sector perform" rating and reduced their price objective for the company from $4.00 to $1.50 in a research report on Thursday, May 8th. The Goldman Sachs Group initiated coverage on Geron in a research report on Thursday, July 10th. They issued a "sell" rating and a $1.00 price objective for the company. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $4.61.

Geron Stock Performance

Shares of GERN traded down $0.02 during mid-day trading on Wednesday, hitting $1.26. The company's stock had a trading volume of 6,746,319 shares, compared to its average volume of 8,612,146. Geron has a one year low of $1.17 and a one year high of $4.89. The company has a debt-to-equity ratio of 0.44, a quick ratio of 6.97 and a current ratio of 7.87. The firm has a market capitalization of $802.52 million, a PE ratio of -6.00 and a beta of 0.64. The stock's 50-day moving average is $1.44 and its two-hundred day moving average is $1.80.

Geron (NASDAQ:GERN - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.01. Geron had a negative return on equity of 47.86% and a negative net margin of 119.54%. The company had revenue of $39.60 million during the quarter, compared to analysts' expectations of $49.88 million. During the same period in the prior year, the business earned ($0.07) earnings per share. Geron's revenue for the quarter was up 12927.3% compared to the same quarter last year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Raymond James Financial Inc. acquired a new position in Geron during the fourth quarter worth $247,000. HighTower Advisors LLC increased its stake in shares of Geron by 33.1% in the fourth quarter. HighTower Advisors LLC now owns 36,041 shares of the biopharmaceutical company's stock valued at $128,000 after buying an additional 8,967 shares in the last quarter. Swiss National Bank increased its stake in shares of Geron by 15.7% in the fourth quarter. Swiss National Bank now owns 1,007,800 shares of the biopharmaceutical company's stock valued at $3,568,000 after buying an additional 136,400 shares in the last quarter. Corient Private Wealth LLC increased its stake in shares of Geron by 58.7% in the fourth quarter. Corient Private Wealth LLC now owns 37,585 shares of the biopharmaceutical company's stock valued at $133,000 after buying an additional 13,896 shares in the last quarter. Finally, Cibc World Markets Corp acquired a new stake in shares of Geron in the fourth quarter valued at $196,000. 73.71% of the stock is owned by institutional investors.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.